What late side effects can lurbinectedin cause, and what gets monitored?
Lurbinectedin’s late side effects are monitored with tests that focus on the organs most often affected during treatment, especially the liver and blood counts. Monitoring commonly includes liver function tests and complete blood counts to detect abnormalities that may persist or appear after cycles. [1]
Which specific lab tests are used?
Clinicians typically use:
- Liver function tests (often including AST, ALT, bilirubin, and alkaline phosphatase) to monitor for ongoing or delayed liver toxicity. [1]
- Complete blood counts (including hemoglobin, white blood cells, and platelets) to monitor for late cytopenias. [1]
Are there other tests depending on symptoms?
If a patient develops symptoms suggesting heart, lung, kidney, or neurologic involvement, clinicians may order additional tests based on the suspected organ (for example, imaging or targeted labs). The provided information, however, specifically points to liver labs and blood counts as the core monitoring tests. [1]
Where do these monitoring needs come from?
These monitoring approaches align with lurbinectedin’s known safety profile in which liver enzyme/bilirubin changes and blood count suppression are key toxicities tracked during therapy and afterward. [1]
Practical: how clinicians usually apply this monitoring over time
Monitoring is done around treatment cycles and continues to confirm recovery after abnormalities, using the same core lab panels (liver function tests and complete blood counts) to decide when it is safe to continue and whether a delayed problem is resolving. [1]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/